Elevated Serum Calcium
Excess parathyroid hormone (PTH) secretion from a single parathyroid adenoma, hyperplasia of the parathyroids, parathyroid carcinoma
Especially tumors of the breast, lung, and kidney in which hypercalcemia may occur from direct bony metastasis
Multiple myeloma that directly degrades bone
Other cancers that produce hypercalcemia by inducing PTH secretion
Excess vitamin D intake
Prolonged use of diuretics and thiazides known to produce hypercalcemia
Severe hypercalcemia favors a diagnosis of cancer.
Commonly Encountered Situations
Hypercalcemia from malignancy is especially common.
Suggested Additional Lab Testing
In primary hyperparathyroidism, serum PTH is increased and serum phosphorus is decreased.
In hypercalcemia of malignancy, serum phosphorus is decreased in approximately 50% of patients, and there is a decrease in the serum PTH in these patients.
Serum protein electrophoresis is useful in the assessment for multiple myeloma. Serum 1,25-dihydroxy vitamin D is low in hypercalcemia of malignancy. It is often increased in primary hyperparathyroidism.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- New Romosozumab BLA Includes Data from Additional Osteoporosis Trials
- Impact of Maternal Diabetes on Outcomes in Very Preterm, Very Low-Birth-Weight Infants
- Age-Related Differences in Manifestation of Cushing Disease Identified